OncoCyte Co. (NASDAQ:OCX - Get Free Report) CEO Josh Riggs purchased 3,390 shares of OncoCyte stock in a transaction on Thursday, April 11th. The shares were acquired at an average cost of $2.95 per share, for a total transaction of $10,000.50. Following the purchase, the chief executive officer now owns 3,505 shares in the company, valued at $10,339.75. The acquisition was disclosed in a document filed with the SEC, which is available through this link.
OncoCyte Stock Performance
OCX stock opened at $2.53 on Tuesday. The business has a fifty day simple moving average of $2.96 and a 200-day simple moving average of $3.06. OncoCyte Co. has a 52 week low of $2.08 and a 52 week high of $6.80.
Institutional Trading of OncoCyte
A number of institutional investors and hedge funds have recently made changes to their positions in OCX. Millennium Management LLC acquired a new stake in shares of OncoCyte during the 2nd quarter worth $896,000. Geode Capital Management LLC increased its holdings in shares of OncoCyte by 23.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,228,553 shares of the company's stock worth $283,000 after buying an additional 236,099 shares during the last quarter. Vanguard Group Inc. increased its holdings in OncoCyte by 2.3% in the 1st quarter. Vanguard Group Inc. now owns 3,986,270 shares of the company's stock valued at $5,940,000 after purchasing an additional 90,534 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in OncoCyte by 17.8% in the 2nd quarter. Goldman Sachs Group Inc. now owns 541,983 shares of the company's stock valued at $487,000 after purchasing an additional 81,979 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in OncoCyte by 131.7% in the 2nd quarter. Renaissance Technologies LLC now owns 138,100 shares of the company's stock valued at $32,000 after purchasing an additional 78,500 shares in the last quarter. 55.35% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Elon’s New A.I. Device is About to Shock the World
From InvestorPlace | Ad
Using this device you see above…
Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in…
“The next step in human evolution.”
Click here to see the details because there’s a lot of money at stake.
A number of brokerages have weighed in on OCX. StockNews.com began coverage on OncoCyte in a research note on Friday. They set a "sell" rating on the stock. Benchmark reissued a "speculative buy" rating and set a $5.00 price target on shares of OncoCyte in a research note on Monday.
Read Our Latest Report on OCX
OncoCyte Company Profile
(
Get Free Report)
OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
